newsfilter
← Latest News
GlobeNewswire·

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- First patient